Fluticasone/formoterol: A new single-aerosol combination therapy for patients with asthma

Respiratory Medicine

Volumn 106, Issue SUPPL. 1, 2012, Pages

  Dissanayake, Sanjeeva ^a   Grothe, Birgit ^a   Kaiser, Kirsten ^b  

^a Mundipharma Research Ltd   (United Kingdom)

^b SkyePharma AG   (Switzerland)

Author keywords

Asthma management; Clinical trial data; Combination therapy; Fluticasone propionate; Formoterol fumarate; Single aerosol inhaler

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO;

ARTICLE; ASTHMA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FORCED EXPIRATION; HEADACHE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MORNING DOSAGE; PARTICLE SIZE; PHARYNGITIS; PRIORITY JOURNAL; RHINOPHARYNGITIS; VIRUS INFECTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AEROSOLS; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; ETHANOLAMINES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84871642745     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/S0954-6111(12)70006-9     Document Type: Article

References (67)

1. GINA Report, Global Strategy for Asthma Management and Prevention Available from: http://www.ginasthma.org/uploads/users/files/GINA-Report-2011. pdf (accessed: August 2012).
2. AP Greening, PW Ind, M Northfield, G Shaw Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group Lancet 344 1994 219 224
3. A Woolcock, B Lundback, N Ringdal, LA Jacques Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids Am J Respir Crit Care Med 153 1996 1481 1488
4. RA Pauwels, CG Lofdahl, DS Postma, AE Tattersfield, P O'Byrne, PJ Barnes et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group N Engl J Med 337 1997 1405 1411
5. PM O'Byrne, PJ Barnes, R Rodriguez-Roisin, E Runnerstrom, T Sandstrom, K Svensson et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial Am J Respir Crit Care Med 164 2001 1392 1397
6. SW Stoloff, DA Stempel, J Meyer, RH Stanford, JR Carranza Rosenzweig Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies J Allergy Clin Immunol 113 2004 245 251
7. C Marceau, C Lemieère, D Berbiche, S Perreault, L Blais Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma J Allergy Clin Immunol 118 2006 574 581
8. ED Bateman, HA Boushey, J Bousquet, WW Busse, TJ Clark, RA Pauwels et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med 170 2004 814 836
9. G Huchon, H Magnussen, A Chuchalin, L Dymek, FB Gonod, J Bousquet Lung function and asthma control with beclomethasone and formoterol in a single inhaler Respir Med 103 2009 41 49
10. PM O'Byrne, H Bisgaard, PP Godard, M Pistolesi, M Palmqvist, Y Zhu et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma Am J Respir Crit Care Med 171 2005 129 136
11. B Ställberg, P Olsson, LA Jörgensen, N Lindarck, T Ekström Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing Int J Clin Pract 57 2003 656 661
12. ED Bateman, M Britton, J Carrillo, J Almeida, C Wixon Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma Clin Drug Invest 16 1998 193 201
13. M Kavuru, J Melamed, G Gross, C Laforce, K House, B Prillaman et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial J Allergy Clin Immunol 105 2000 1108 1116
14. L Cazzoletti, A Marcon, C Janson, A Corsico, D Jarvis, I Pin et al. Asthma control in Europe: a real-world evaluation based on an international population-based study J Allergy Clin Immunol 120 2007 1360 1367
15. MR Partridge, T van der Molen, SE Myrseth, WW Busse Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study BMC Pulm Med 6 2006 13
16. J Haughney, D Price, A Kaplan, H Chrystyn, R Horne, N May et al. Achieving asthma control in practice: understanding the reasons for poor control Respir Med 102 2008 1681 1693
17. R Horne, D Price, J Cleland, R Costa, D Covey, K Gruffydd-Jones et al. Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med 7 2007 8
18. S Accordini, M Bugiani, W Arossa, S Gerzeli, A Marinoni, M Olivieri et al. Poor control increases the economic cost of asthma. A multicentre population-based study Int Arch Allergy Immunol 141 2006 189 198
19. P Demoly, P Paggiaro, V Plaza, SC Bolge, H Kannan, B Sohier et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK Eur Respir Rev 18 2009 105 112
20. European Lung Foundation Areas for action Available from: http://www.european-lung-foundation.org/47-european-lung-foundation-elf-areas- for-action.htm (accessed: August 2012).
21. J Bousquet, C Winchester, A Papi, C Virchow, J Haughney, D Costa et al. Inhaled corticosteroid/long-acting beta2-agonist combination therapy for asthma: attitudes of specialists in Europe Int Arch Allergy Immunol 157 2012 303 310
22. NK Leidy, B Gutierrez, K Lampl, T Uryniak, CD O'Brien Can patients with asthma feel inhaler therapy working right away? Two clinical trials testing the effect of timing of assessment on patient perception J Asthma 46 2009 1006 1012
23. KR Murphy, BG Bender Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence J Asthma Allergy 2 2009 63 72
24. AB Hauber, AF Mohamed, FR Johnson, D Meddis, S Wagner, L O'Dowd Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications Allergy Asthma Proc 30 2009 139 147
25. CK Lai, TS De Guia, YY Kim, SH Kuo, A Mukhopadhyay, JB Soriano et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study J Allergy Clin Immunol 111 2003 263 268
26. BG Bender, A Long, B Parasuraman, ZV Tran Factors influencing patient decisions about the use of asthma controller medication Ann Allergy Asthma Immunol 98 2007 322 328
27. Mundipharma International Ltd. flutiform combined SPC; 2011.
28. 2-agonist combinations in the treatment of asthma Respir Med 106 Suppl 1 2012 S4 S8
29. Price D. Trends in prescribing of inhaled corticosteroids alone and in combination with long-acting beta2-agonists in Europe in 2004-2009. Abstract presented at World Allergy Congress, 5-8 December 2010, Dubai, UAE.
30. NP Adams, JC Bestall, P Jones, TJ Lasserson, B Griffiths, CJ Cates Fluticasone at different doses for chronic asthma in adults and children Cochrane Database Syst Rev 2009 CD003534
31. DE Mager, N Moledina, WJ Jusko Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation J Pharm Sci 92 2003 1521 1525
32. M Johnson Development of fluticasone propionate and comparison with other inhaled corticosteroids J Allergy Clin Immunol 101 1998 S434 S439
33. Flixotide 50, 125, 250 micrograms Evohaler Available from: http://www.medicines.org.uk/emc/medicine/2913/SPC/Flixotide++50,+125, +250+micrograms+Evohaler/PHARMACOLOGICAL-PROPS (accessed: July 2012).
34. S Rohatagi, S Appajosyula, H Derendorf, S Szefler, R Nave, K Zech et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective J Clin Pharmacol 44 2004 37 47
35. HW Kelly Comparison of inhaled corticosteroids: an update Ann Pharmacother 43 2009 519 527
36. H Derendorf, R Nave, A Drollmann, F Cerasoli, W Wurst Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Eur Respir J 28 2006 1042 1050
37. WE Berger The use of inhaled formoterol in the treatment of asthma Ann Allergy Asthma Immunol 97 2006 24 33
38. M Palmqvist, P Arvidsson, O Beckman, S Peterson, J Lotvall Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers Pulm Pharmacol Ther 14 2001 29 34
39. MJ Politiek, M Boorsma, R Aalbers Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction Eur Respir J 13 1999 988 992
40. M Palmqvist, G Persson, L Lazer, J Rosenborg, P Larsson, J Lotvall Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency Eur Respir J 10 1997 2484 2489
41. JA van Noord, JJ Smeets, JA Raaijmakers, AM Bommer, FP Maesen Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action Eur Respir J 9 1996 1684 1688
42. J Corren, L Mansfield, T Pertseva, V Blahzko, K Kaiser Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered separately in the treatment of adolescent and adult patients with moderate to severe asthma Respir Med 2012 10.1016/j.rmed.2012.10.025 [Epub ahead of print].
43. R Nathan, A D'Urzo, V Blahzko, K Kaiser Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild to moderate asthma BMC Pulm Med 12 2012 67
44. DS Pearlman, CF LaForce, K Kaiser Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone Eur Respir J 38 2011 727s
45. T Pertseva, S Dissanayake, K Kaiser Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Eur Respir J 40 2012 P2191
46. A Bodzenta-Lukaszyk, G Pulka, A Dymek, D Bumbacea, T McIver, B Schwab et al. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler Respir Med 105 2011 674 682
47. A Bodzenta-Lukaszyk, A Dymek, K McAulay, H Mansikka Fluticasone/ formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study BMC Pulm Med 11 2011 28
48. R Aalbers, G Brusselle, A Bodzenta-Lukaszyk Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study Adv Ther 29 2012 958 969
49. A Bodzenta-Lukaszyk, R Buhl, B Balint, M Lomax, K Spooner Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomised, controlled, non-inferiority trial of efficacy and safety J Asthma 2012 Oct 26 10.3109/02770903.2012.719253 [Epub ahead of print].
50. A Mansur, K Kaiser Long-term safety and efficacy of fluticasone/ formoterol combination therapy in patients with asthma J Aerosol Med Pulm Drug Deliv 2012 Oct 25 10.1089/jamp.2012.0977 [Epub ahead of print].
51. JM FitzGerald, LP Boulet, RM Follows The CONCEPT trial: a 1 -year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma Clin Ther 27 2005 106 393
52. MK Tulic, P Christodoulopoulos, Q Hamid Small airway inflammation in asthma Respir Res 2 2001 333 339
53. PR Burgel, J de Blic, P Chanez, C Delacourt, P Devillier, A Didier et al. Update on the roles of distal airways in asthma Eur Respir Rev 18 2009 80 95
54. PH Howarth Why particle size should affect clinical response to inhaled therapy J Aerosol Med 14 Suppl 1 2001 S27 S34
55. OS Usmani, MF Biddiscombe, PJ Barnes Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size Am J Respir Crit Care Med 172 2005 1497 1504
56. J Heyder Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery Proc Am Thorac Soc 1 2004 315 320
57. J Heyder, J Gebhart, G Rudolf, CF Schiller, W Stahlhofen Deposition of particles in the human respiratory tract in the size range 0.005-15 mm J Aerosol Sci 17 1986 811 825
58. JN Pritchard The influence of lung deposition on clinical response J Aerosol Med 14 Suppl 1 2001 S19 S26
59. WH Finlay Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols J Aerosol Sci 28 1997 1301 1309
60. SP Newman Aerosol deposition considerations in inhalation therapy Chest 88 1985 152S 160S
61. R Mueller-Walz, L-M Fueg, A Brindley, G Venthoye Delivery from flutiform(tm) HFA pressurized metered dose inhaler (pMDI) with and without valved holding chamber (VHC) Resp Drug Deliv 2 2011 431 434
62. JP Mitchell, MW Nagel Particle size analysis of aerosols from medicinal inhalers KONA 22 2004 32 65
63. SP Newman, HK Chan In vitro/in vivo comparisons in pulmonary drug delivery J Aerosol Med Pulm Drug Deliv 21 2008 77 84
64. C Richardson, M de Matas, H Hosker, R Mukherjee, I Wong, H Chrystyn Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization Pharm Res 24 2007 2008 2017
65. KF Chung, G Caramori, IM Adcock Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future Eur J Clin Pharmacol 65 2009 853 871
66. BHM Johal, M Fischer, J Marshall Comparison of the fine particle fraction of fluticasone propionate/formoterol fumarate combination with other combination products Eur Respir J 40 2012 56s
67. TE Delea, RH Stanford, M Hagiwara, DA Stempel Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs Curr Med Res Opin 24 2008 3435 3442